# French regulator authorizes Sensorion hearing-loss gene-therapy trial

_Thursday, September 3, 2026 at 2:52 AM EDT · Policy · Latest · Tier 2 — Notable_

![French regulator authorizes Sensorion hearing-loss gene-therapy trial — Primary](https://cdn.rttnews.com/images/v4/RTTNews-logo-512x512.png)

France's medicines regulator, ANSM, has authorized Sensorion to begin HearConnex, a Phase I/II trial of its SENS-601 gene-therapy candidate for GJB2-related hearing loss, RTTNews reported.

The open-label study will first assess safety and tolerability through unilateral intra-cochlear dosing across two ascending-dose cohorts, then evaluate efficacy after bilateral administration in an expansion cohort. The trial will also assess Sensorion's injection system. Site-startup work is underway in France; the company targets first-patient dosing in early 2027 and clinical data generation during 2027.

## Sources

- [RTTNews](https://www.rttnews.com/3688105/sensorion-secures-ansm-approval-to-launch-phase-i-ii-hearconnex-trial-of-sens-601-in-france.aspx)

---
Canonical: https://techandbusiness.org/newswire/oLWC8qbe_mdAUoDgDtZal4
Retrieved: 2026-09-03T09:28:23.752Z
Publisher: Tech & Business (techandbusiness.org)